Automation is an area where life scientists often see opportunities for innovation; doing the same technique day in and day
out unsurprisingly brings to mind ways to ease and speed the process. If you’ve invented an automated tool, colleagues in
other labs could very likely benefit from your ingenuity. But if you’ve ever dreamt of seeing your invention in a product
catalog, you’d best keep in mind that taking your tool to market is rarely simple.
Indeed, developing a good tool and a good product can seem like an uphill battle. Some areas of lab automation are dominated
by big companies; amid that kind of competition, newcomers may need to drop their price. To create and sell a product, you’ll
also probably have to stretch outside your scientific comfort zone. Commercializing a product is a multi-step process, from
the legwork of tuning and tweaking a complex prototype of moving parts, to the back-and-forth dialogue with potential users
and customers, the intimate knowledge of your market and how it might change, and the sales pitch to people you don’t know.
“Before people start spending money on [developing] a product, we want them to think about the value chain and how the industry
ecosystem is organized,” says Veronika Litinski, health-care and life sciences practice lead at the MaRS Centre, a Toronto-based
innovation cluster that engages researchers in commercializing their inventions. “If some market seems available, you have
to understand why.” For example, it could be that the niche is too difficult to fill using the technologies currently available
or that the solutions available are too expensive or difficult to operate. The only way to know is by asking questions.
The Scientist spoke with researchers who are automating and commercializing the latest technologies to aid life science work. Here are
their thoughts for getting over the hurdles:
Scientist: Ameer Taha, founder, Certo
Labs, Toronto
Product: Certo-Ex, an automated system
that homogenizes and extracts chemicals
from animal tissue and food
Status: Recently tested a proof-of-concept
prototype and currently developing the
first market-ready product
The story: As a master’s student in
nutrition, Taha spent a lot of time grinding
and extracting nutrients from rat tissues.
Inspired to design an instrument that would
automate this process, he formed a partnership
with his brother, Ahmed, then an
undergraduate pharmacology student who
had won several business plan competitions.
Later, through their interactions with
MaRS, they were introduced to and formed
a partnership with industrial designer Lahav
Gil of Toronto-based Kangaroo Design &
Innovation.
The struggle: Automating a process
doesn’t in itself guarantee that you’ll gain
in throughput, Ameer says. “What ended
up happening was, we tried running some samples with the semiautomated machine
that we had initially, but we didn't save
much time," he recalls. "We had to come
up with a novel way to make the chemistry
more efficient."
Using a grant awarded from the
Ontario Centers of Excellence, Ameer
and Gil went back to work on the design.
Ameer worked with collaborators at the
University of Waterloo to simplify the
chemistry involved in extracting nutrients
and toxins from the samples. Gil developed
an autohomogenizer that streamlines the
steps from grinding to cleaning. The group
soon filed for a patent that allows them
to extract chemicals at least eight times
quicker than conventional methods at a
fraction of the cost.
Considerations: "The real successful
products tend to start in niches, where the
customer pain is significant," says Litinski,
who helped Ameer's team gather market
research. "So for example, when you're
talking about sample prep of solid materials
that require extraction, it's a very laborintensive
process."
Still, even though they knew they had hit
a niche, the group worked for more than 6
months to identify potential customers and
their needs. It took them more than a dozen
informational interviews to "paint a more
refined picture of where the gaps really are,"
Litinski says.
Cost: $500,000 thus far to develop the
product
Scientist: Neil Benn, CEO , Ziath Ltd,
Cambridge, UK
Products: Automated 2D barcode scanners
and software, to keep track of large
volumes of samples in drug discovery and
clinical applications
Status: Selling and expanding product line
The story: Benn had 15 years of experience
working in large and small biotech companies,
tending large machines and writing
software used to process millions of experimental
samples. He and his colleague Tim
Dilks decided that there had to be an easier
way to keep track of all the racks of tubes, so
they created a system that scans them.
The struggle: Benn had no experience
in sales or marketing, but early on, he and
Dilks took their products to conferences
to meet and talk with potential customers.
At the time, they figured that since they
were already in the business, they knew
what customers will need. Looking for more
detailed information on how to break into
new markets, they eventually partnered with
a sales and marketing specialist.
“It’s great that you’re passionate, but you’re confusing the customer when you tell them about the small things you’re doing
to make it really good.”
That person also gave Benn a lesson
that he didn't expect: how to sell. What he's
learned is, keep it simple. "If you have your
own thing that you produce, then you're naturally
very proud of it," he recalls. "I was like
a 5-year-old with a Christmas present." To
which the specialist told him, "It's great that
you're passionate, but you're confusing the
customer when you tell them about the small
things you're doing to make it really good."
Enthusiasm about your product will be appreciated,
but stick with the product details that
are most relevant to the customer, Benn adds.
Considerations: If you don't have an
intimate knowledge of what the customer
wants, or you don't enjoy talking with people
to find out, then you should hire a sales and
marketing specialist sooner rather than later,
Benn says. Above all, let people know that
the product exists and how its advantages fit
with the customer's processes. "That's one
lesson I didn't do at first."
Cost: About £30,000 ($50,000 USD)
spent over two years, to start up the business
and develop a prototype
Scientist: David Beebe, biomedical engineer,
University of Wisconsin, Madison
Products: the iuvo Chemotaxis Array and
the iuvo Single Array formatted for cell invasion
assays, for use with existing automated
liquid handlers or handheld pipetters
Status: Partnered with BellBrook Labs;
arrays currently in field testing
The story: In 2001, one of Beebe's graduate
students was pipetting tiny droplets
containing cells onto a microfluidic chip he
had made. When he completely missed one
of the wells, the drop of fluid diffused into
its correct location via a surface tensioninduced
pressure, surprising everyone in the
lab. Rather than jamming a pipette into the
tiny wells, they realized, they could harness
passive diffusion. "At the time, we knew
that we'd stumbled onto this elegant way to
pump fluid," Beebe recalls.
The struggle: Although the initial
discovery was lucky, transforming even the
simplest microfluidics tools into commercial products for drug development is tricky, says
Beebe. The original prototype was made
of a silicon rubber that absorbs drugs, so it
would not have been useful for drug screening
assays. Researchers from Wisconsinbased
BellBrook Labs led the development
using standard cell-culture plastics. But
creating microscale impressions on the plastics,
while maintaining clarity and flatness,
was a challenge that added 18 months to
the process, says Steve Hayes, BellBrook's
director of research and development. "In
the end, it involved a large infrastructure and
new tools for forming plastics," he says. The
benefit is that the resulting array is simple
and requires no moving parts.
Considerations: Learn about the existing
market and what you'll have to compete
against. Sometimes those areas are moving
targets, Beebe says. For example, since the
microfluidics technologies took off a decade
ago, cell-culture plates have improved substantially,
from 24-well plates to 384 wells
and beyond. That means it will be more
difficult to market a product based on the
argument that microfluidics devices will use
smaller volumes, he adds.
Cost: The arrays will be sold for $200-
$300 each.
Scientist: Yu Sun, founder, Marksman
Cellject, Toronto
Product: Model ZeF 701, an automated
tool for cell and embryo microinjection and
manipulation
Status: Prototype in on-site trial in a clinic
using patient samples
The Story: Ten years ago, engineer Yu
Sun started working to create a system
that would reliably inject cells or embryos
with DNA, RNA, and sperm. It's a finicky
technique; to learn how to do this by hand,
researchers typically train for at least one
year, and many never develop a good hit rate.
The struggle: A common pitfall for
researchers is realizing the vast gulf between
a prototype and a fully tested product, Sun
says. "It's not only about [tweaking computer]
code or beautifying your system"—
it's about user-oriented design and testing,
he says. Sun in particular needed to see
whether the automation reliably served
the needs of two very different end users:
research laboratories doing basic science
and hospitals doing in vitro fertilization.
For both sets of users, testing should
start during product development, and
developers should regularly interact with users. It's not enough to interview them, Sun
insists: "Observe them, and pay attention to
the details of what they're doing, and then
do what they're doing," he says—that way,
you can understand the physical process a
human must go through to perform the task
at hand, and where your tool fits in.
Research laboratories tend to have a
more varied set of experimental conditions
and needs, whereas hospitals and clinics
usually want a consistent and standardized
system. Sun says he has met several
clinicians who are interested in purchasing
the system to use it for in vitro fertilization,
provided the trials produce good data. "Your
future customers will never really care or
have the guts to adopt your system until they
see the data, under real conditions," he says.
Considerations: When considering a
clinical setting as a market for your product,
take time early in the process to understand
the stringent regulations set by the U.S. Food
and Drug Administration and other agencies.
Marksman Cellject hired two consultants
to help navigate these regulations.
Cost: The company plans to sell the
system for $190,000 and make it available
for lease for $40,000.